ARCHIVES

DC Board Okay One Recompetition, Disapproves Two

This article is from The Cancer Letter archive.

Vol. 08 No. 44 | November 12, 1982

Download PDF Visit The Full Archive

Related Articles

QOL With Femara Comparable To Placebo, Analysis Finds

December 26, 2003

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

In Brief: Nurses Association Endorses Clinton-Gore; Levin Heads New Society For Neuro-Oncology

June 28, 1996

Abstracts of Papers From ASCO Meeting

April 14, 1978

NCI May Seek Cuts In R01s, P01s If Congress Approves Rescission

January 30, 1981

Sarcoma Survivors At Risk Of Blood Clots, Study Finds

May 25, 2007